Medication
Infanrix-Ipv/hib
DIN 02257122 · Glaxosmithkline Inc
What it is
- Active ingredients
- Pertussis Toxoid — 25 mcg
- Filamentous Haemagglutinin — 25 mcg
- Pertactin — 8 mcg
- Diphtheria Toxoid — 30 unit
- Tetanus Toxoid — 40 unit
- Inactivated Poliovirus Type I — 40 unit
- Inactivated Poliovirus Type II — 8 unit
- Inactivated Poliovirus Type III — 32 unit
- Haemophilus Influenzae Type B-prp And Tetanus Toxoid Conjugate — 10 mcg
- Form and route
- Suspension · Intramuscular
- Schedule
- SCHEDULE D
- Authorised since
- 2012-10-25
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
No other medication authorised in Canada shares this active ingredient.
Health Canada groups products by their active ingredients. No other marketed product shares this one’s group, which usually means it is still the only authorised version — not that alternatives were hidden or missed.
How it is classified
- Anatomical main group
- Anti-infectives for systemic use
- ATC code
- J07CA06
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of J07CA06, see the WHO ATC/DDD Index.
Recalls and safety alerts
Recall matching is not available yet.
RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.